How ACE-031 works
An experimental muscle-growth protein whose Duchenne program stopped over bleeding concerns.
Also called: Ramatercept, ACE031, ActRIIB-IgG1, ActRIIB-Fc.
Myostatin pathway · Soluble activin receptor IIB–IgG1 Fc fusion protein.
ACE-031 is a decoy receptor that traps myostatin, activins and related signals before they reach cells. This can increase muscle size. It also affects signals outside muscle, which helps explain concern about blood-vessel changes and bleeding.
- Myostatin / GDF-8 and activins: Traps ligands that normally restrain muscle growth.
- BMP and other TGF-beta family signals: Broad binding can affect tissues beyond muscle; vascular effects are a safety concern.
Half-life: Mean terminal half-life 10–15 days after a single subcutaneous trial dose.
Related to ACE-031
- Follistatin-344: Human gene-therapy findings do not establish a dose for follistatin-344 protein vials.
- Ipamorelin: An experimental peptide that triggers growth hormone release.
- Hexarelin: A peptide that releases growth hormone; repeated use can weaken the response.
Sources
- 503B Bulk Drug Substances List, FDA · FDA · 2026
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act, FDA · FDA · 2026
- Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act, FDA · FDA · 2026
- Cellulitis, NHS · NHS · 2026
- Find product information about medicines, Medicines and Healthcare products Regulatory Agency · MHRA · 2026
- Medicines, European Medicines Agency · European Medicines Agency · 2026
- Pyrogen and Endotoxins Testing: Questions and Answers, FDA · 2026
- The 2026 Prohibited List, World Anti-Doping Agency · WADA · 2026
- Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026, Australian Government · Australian Government · 2026
- Anaphylaxis, NHS · NHS · 2023
- Definition of the Term “Biological Product” Final Regulatory Impact Analysis, FDA · 2020
- Australian Register of Therapeutic Goods (ARTG), Therapeutic Goods Administration · TGA
- Mixing, Diluting, or Repackaging Biological Products Outside the Scope of an Approved Biologics License Application Guidance for Industry, FDA
- Nosebleed, NHS
- Search criteria - Drug Product Database online query, Health Canada · Health Canada
Sources checked: 2026-10-18.
Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.